What is new in India’s COPD inhaler market? Lupin has launched Formoflo-G MDI, a fixed-dose triple-combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD), after approval from the Drug Controller General of India (DCGI). The company calls it the first product of its kind in the world, a claim we look at closely below. It combines three medicines in one device for patients with moderate to severe COPD.
Quick answer: what is Formoflo-G?
- What it is: a fixed-dose triple-combination metered-dose inhaler (MDI) from Lupin, approved by the DCGI.
- What is inside: glycopyrronium bromide, formoterol fumarate and fluticasone propionate.
- Who it is for: long-term management of moderate to severe COPD, taken twice daily.
- What is unknown: price, launch pace and strengths were not disclosed in the company statement.
- The claim to read carefully: “world’s first” is the company’s own description.
What is inside the inhaler, and what does each part do?
Triple therapy for COPD usually means combining a long-acting muscarinic antagonist, a long-acting beta-agonist and an inhaled corticosteroid. Formoflo-G follows that pattern. The table below explains each ingredient in plain language.
| Ingredient | Drug class | Role in COPD |
|---|---|---|
| Glycopyrronium bromide | Long-acting muscarinic antagonist (LAMA) | Relaxes airway muscle to keep airways open |
| Formoterol fumarate | Long-acting beta-agonist (LABA) | Opens the airways and eases breathlessness |
| Fluticasone propionate | Inhaled corticosteroid (ICS) | Reduces airway inflammation |
The classification above is standard pharmacology rather than a statement from the company. Doses per puff were not included in the material we reviewed, so we do not report them.
Why combine three drugs in one device?
COPD is a long-term lung condition in which airflow is persistently limited, most often because of smoking or long exposure to polluted air, as described on the WHO COPD fact sheet. International guidance from the GOLD initiative describes stepping up from one bronchodilator to two, and then adding an inhaled corticosteroid for selected patients who continue to have flare-ups.
The practical problem is that patients who need all three often carry two or three separate inhalers, each with its own technique and schedule. A single device can cut the number of steps, simplify the routine and, in principle, help people take their medicines more consistently. In our assessment, simplicity is the strongest argument for any fixed-dose combination, because missed or incorrectly used doses are a leading reason inhaled therapy underperforms.
How big is the COPD problem in India?
Lupin says more than 55 million people in India live with COPD, which would make it one of the leading causes of death and disability in the country. That figure is the company’s, and estimates vary by survey method, but the direction is not in dispute: COPD is common, underdiagnosed and often detected late, when lung function has already fallen.
Lupin also says it ranks second in India’s respiratory segment based on IQVIA data to March 2026, which explains why the company is investing in new respiratory formats. This is a company-cited market position that we have not independently verified.
Is it really the world’s first?
Here is where precision matters. Lupin describes Formoflo-G as the world’s first fixed-dose triple-combination MDI for COPD management in India. To our knowledge, fixed-dose triple inhalers, including pressurised metered-dose versions, are already marketed in other countries, and dry-powder triple inhalers are widely available. The company’s claim therefore appears to rest on this specific combination of molecules in this device format, or on the India context, rather than on triple therapy being new to the world.
We have not seen a regulatory document that defines the claim, so please treat “world’s first” as company-reported. Readers who need to compare products should check the approved prescribing information once it is public.
What we do not know yet
- Price: not disclosed. Affordability will decide uptake in a market where many COPD patients pay out of pocket.
- Availability: no timeline for supply across cities and chemists was stated.
- Clinical data: the statement did not detail trial results, so the evidence base for this exact product is not clear from public material.
- Device details: inhaler technique, spacer compatibility and dose counters were not described.
What should patients and caregivers do?
Formoflo-G is prescription-only and is intended for patients with moderate to severe disease. Nobody should switch inhalers on their own. Patients who are already stable on another regimen should talk to their pulmonologist or physician first, because stepping up or changing the corticosteroid component is a medical decision. People who use an MDI should also ask for a demonstration of technique, since poor coordination between pressing and breathing in is a common reason doses fail to reach the lungs.
The business angle
Nilesh Gupta, Lupin’s Managing Director, said the launch reflects the company’s commitment to addressing unmet patient needs through differentiated, high-quality therapies. Rajeev Sibal, President of India Region Formulations, said it would give healthcare professionals another treatment choice for appropriate COPD patients. Both statements are promotional by nature, but they signal that Indian pharmaceutical companies are moving beyond generics into differentiated delivery formats. Visit the Lupin website for the company’s respiratory portfolio.
For more on how drug approvals and deals are reshaping the sector, browse our pharmaceutical coverage or read about the EPCORE DLBCL-2 trial.
Frequently asked questions
What is Formoflo-G MDI used for?
It is used for the long-term management of moderate to severe COPD, according to Lupin.
What drugs does Formoflo-G contain?
Glycopyrronium bromide, formoterol fumarate and fluticasone propionate, delivered by a metered-dose inhaler.
How often is it taken?
The company describes it as a twice-daily medicine. Exact dosing instructions will be on the prescribing information.
Is Formoflo-G a rescue inhaler?
No. A maintenance combination like this is meant for regular daily use, not for sudden breathlessness. Ask your doctor which inhaler to use for rescue relief.
What does it cost?
The price has not been disclosed in the announcement we reviewed.
Is it approved in India?
Yes, Lupin says it received approval from the DCGI.
How we reported this
This article is based on Lupin’s announcement dated 6 October 2026 and public health references linked above. Company statements are attributed to the company, and market-position and prevalence figures are company-cited. Background on drug classes is general pharmacology. Statements labelled as our assessment are opinion. Last updated 7 October 2026. This is general information, not medical advice; consult a doctor about any inhaler.